The mechanisms of action of rituximab in the elimination of tumor cells

被引：204

作者：

Johnson, P ^{[1
]}

Glennie, M ^{[1
]}

机构：

[1] Univ Southampton, Sch Med, Canc Sci Div, Southampton, Hants, England

来源：

SEMINARS IN ONCOLOGY | 2003年 / 30卷 / 01期

关键词：

D O I：

10.1053/sonc.2003.50025

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3 / 8

页数：6

共 35 条

[1]

Alas S, 2000, ANTICANCER RES, V20, P2961

[2]

Alas S, 2001, CANCER RES, V61, P5137

[3]

Alas S, 2001, CLIN CANCER RES, V7, P709

[4] Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma [J].

Anderson, DR ;

GrilloLopez, A ;

Varns, C ;

Chambers, KS ;

Hanna, N .

BIOCHEMICAL SOCIETY TRANSACTIONS, 1997, 25 (02) :705-708

[5] TRANSFECTION OF THE CD20 CELL-SURFACE MOLECULE INTO ECTOPIC CELL-TYPES GENERATES A CA2+ CONDUCTANCE FOUND CONSTITUTIVELY IN B-LYMPHOCYTES [J].

BUBIEN, JK ;

ZHOU, LJ ;

BELL, PD ;

FRIZZELL, RA ;

TEDDER, TF .

JOURNAL OF CELL BIOLOGY, 1993, 121 (05) :1121-1132

[6] The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction [J].

Byrd, JC ;

Kitada, S ;

Flinn, IW ;

Aron, JL ;

Pearson, M ;

Lucas, N ;

Reed, JC .

BLOOD, 2002, 99 (03) :1038-1043

[7] Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene [J].

Cartron, G ;

Dacheux, L ;

Salles, G ;

Solal-Celigny, P ;

Bardos, P ;

Colombat, P ;

Watier, H .

BLOOD, 2002, 99 (03) :754-758

[8] Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets [J].

Clynes, RA ;

Towers, TL ;

Presta, LG ;

Ravetch, JV .

NATURE MEDICINE, 2000, 6 (04) :443-446

[9] Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden:: clinical and molecular evaluation [J].

Colombat, P ;

Salles, G ;

Brousse, N ;

Eftekhari, P ;

Soubeyran, P ;

Delwail, V ;

Deconinck, E ;

Haïoun, C ;

Foussard, C ;

Sebban, C ;

Stamatoullas, A ;

Milpied, N ;

Boué, F ;

Taillan, B ;

Lederlin, P ;

Najman, A ;

Thièblemont, C ;

Montestruc, F ;

Mathieu-Boué, A ;

Benzohra, A ;

Solal-Céligny, P .

BLOOD, 2001, 97 (01) :101-106

[10] Rituximab in combination with CHOP or fludarabine in low-grade lymphoma [J].

Czuczman, MS ;

Fallon, A ;

Mohr, A ;

Stewart, C ;

Bernstein, ZP ;

McCarthy, P ;

Skipper, M ;

Brown, K ;

Miller, K ;

Wentling, D ;

Klippenstein, D ;

Loud, P ;

Rock, MK ;

Benyunes, M ;

Grillo-López, AJ ;

Bernstein, SH .

SEMINARS IN ONCOLOGY, 2002, 29 (01) :36-40

← 1 2 3 4 →